Search clinical trials for: MK-4827

Total 1741 results

Southern Illinois University
Merck Sharp & Dohme LLC

Active, not recruiting

MK-3475/BCG in High Risk Superficial Bladder Cancer (MARC)

Bladder Cancer

United States
Afferent Pharmaceuticals, Inc.

Completed

A 12-Week Study in Participants With Refractory Chronic Cough (MK-7264-012)

Refractory Chronic Cough
Incyte Corporation

Terminated

A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors

Solid Tumors

United States
Merck Sharp & Dohme LLC

Completed

A Study of Dalotuzumab (MK-0646) in Breast Cancer Patients (MK-0646-013)

Breast Cancer
Janssen Research & Development, LLC

Completed

A Study to Investigate the Regional Brain Kinetics of the Positron Emission Tomography Ligand 11C-MK-3168 and the Blocking of the Retention of the Ligand in the Human Brain by JNJ-42165279

Healthy

Belgium
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)

Carcinoma, Hepatocellular

United States, Australia, Canada, Chile, China, Colombia, France, Germany, Ireland, Italy, Japan, Korea, Republic of, Mexico, New Zealand, Poland, Russian Federation, Spain, Taiwan, Thailand, Turkey, United Kingdom
Bausch Health Americas, Inc.

Terminated

Study of Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis (AMVISION-1)

Psoriatic Arthritis

United States, Italy, Spain, Hungary, Belgium, Mexico, Poland, Switzerland, United Kingdom, Russian Federation, Canada, Greece, France, Bulgaria, Slovakia, Estonia, Czech Republic
National Cancer Institute (NCI)

Completed

AZD1775 for Advanced Solid Tumors

Solid Tumors

United States
Merck Sharp & Dohme LLC

Withdrawn

First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)-China Extension Study

Esophageal Neoplasms

China
Merck Sharp & Dohme LLC

Withdrawn

Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)

Multiple Myeloma

United States, Canada, France, Israel, Spain, Sweden
NHS Greater Glasgow and Clyde
Merck Sharp & Dohme LLC; Cancer Research UK; University of Southampton; Queen's... and other collaborators

Unknown

Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)

Pancreatic Neoplasms | Mesothelioma | Carcinoma, Non-small-cell Lung

United Kingdom
M.D. Anderson Cancer Center
Memgen, LLC

Withdrawn

Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma

Melanoma
Yaakov Stern
National Institute on Aging (NIA)

Recruiting

Tau PET in Imaging and Cognition: Healthy Adults From 55-90

Aging | Mild Cognitive Impairment

United States
Merck Sharp & Dohme LLC

Completed

A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)-China Extension

Chronic Cough

China
Merck Sharp & Dohme LLC

Completed

Biomarkers of Intestinal Mucosal Healing in Crohn's Disease (P08143)

Crohn Disease
Maastricht University Medical Center

Completed

Dose-finding Study for Vitamin K2 in Human Volunteers

Vitamin K-status

Netherlands
Merck Sharp & Dohme LLC

Completed

A Study of the Combination Regimen Grazoprevir (MK-5172) and Elbasvir (MK-8742) ± Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035) (C-WORTHy)

Hepatitis C
Nisha Mohindra, MD
Merck Sharp & Dohme LLC; Hoosier Cancer Research Network; Celgene Corporation

Terminated

Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC

Non-Small Cell Lung Cancer

United States
Heidelberg University
Merck Sharp & Dohme LLC

Recruiting

Effects of Riociguat on RIght VEntricular Size and Function in PAH and CTEPH (RIVERII)

Chronic Thromboembolic Pulmonary Hypertension | Primary Pulmonary Arterial Hypertension

Germany
Merck Sharp & Dohme LLC

Completed

Respiratory Syncytial Virus (RSV) Human Challenge Study of Molnupiravir in Healthy Participants (MK-4482-017)

Respiratory Syncytial Virus

United Kingdom
Emory University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; National Institutes...

Active, not recruiting

Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer

Recurrent Skin Carcinoma | Skin Squamous Cell Carcinoma

United States
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012)

Cancer | Solid Tumor
Merck Sharp & Dohme LLC

Terminated

Trial Investigating the Efficacy and Safety of SCH 900435 (Org 25935) in Relapse Prevention in Participants With Alcohol Dependence (P05718) (OD-H)

Alcoholism
Merck Sharp & Dohme LLC

Completed

Comparing 4.0 mg.Kg-1 Sugammadex With Placebo in the Reversal of Profound Neuromuscular Blockade (P05767)

Anesthesia | Neuromuscular Blockade
Bispebjerg Hospital

Recruiting

The InterVitaminK Trial - Effects of Vitamin K Supplementation on Cardiovascular, Metabolic, and Bone Health (InterVitaminK)

Coronary Artery Calcification | Arterial Stiffness

Denmark
Fundacion Clinic per a la Recerca Biomédica

Unknown

Efficacy of GZR/EBR in Early Chronic Hepatitis C in HIV/HCV Co-infected Patients (EARLY-HEP-C)

Hepatitis C | HIV

Spain
Merck Sharp & Dohme LLC

Completed

Pharmacodynamics and Efficacy of MK-7288 in Adults With Sleep Apnea (MK-7288-010)

Apnea, Sleep
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Vibostolimab Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001) ( KEYVIBE-001)

Neoplasms
Peking University

Not yet recruiting

Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
National Cancer Institute (NCI)

Active, not recruiting

Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240)

Hepatocellular Carcinoma
Epizon Pharma, Inc.

Completed

A Clinical Trial of Epizon-701 (EPN-701) in Subjects With End-Stage Renal Disease (ESRD)

End-Stage Renal Disease (ESRD)

United States
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019) (APECS)

Alzheimer's Disease | Amnestic Mild Cognitive Impairment | Prodromal Alzheimer's Disease
Peter MacCallum Cancer Centre, Australia

Completed

Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475 (BOSTON II)

Breast Neoplasms | Bone Neoplasms

Australia
Merck Sharp & Dohme LLC

Completed

A Study to Test MK-0941 in Adults With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0941-018)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

An Investigational Drug Study in Adults With Type 2 Diabetes on Basal Insulin (MK-0941-006)

Type 2 Diabetes Mellitus
National Heart, Lung, and Blood Institute (NHLBI)
University of California, San Francisco; RTI International; Versiti; Blood Systems... and other collaborators

Completed

Hemoglobin and Iron Recovery Study (HEIRS)

Recovery of Hemoglobin and Iron Stores After Blood Donation

United States
BioInvent International AB
Merck Sharp & Dohme LLC

Recruiting

A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (KEYNOTE-A04)

Solid Tumor, Adult

United States, Sweden
Merck Sharp & Dohme LLC

Terminated

A Study of Intratumoral/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Malignancies (V938-001)

Neoplasm Metastasis

United States, Canada, Israel
Peloton Therapeutics, Inc.

Active, not recruiting

A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)

Kidney Cancer | Clear Cell Renal Cell Carcinoma | Glioblastoma | Solid Tumor | Glioblastoma Multiforme | Advanced Solid Tumors | GBM | Solid Tumor, Adult | Solid Carcinoma | Glioblastoma, Adult | ccRCC | RCC, Clear Cell Adenocarcinoma | RCC | Renal Cell Carcinoma, Metastatic | Renal Cell Carcinoma Recurrent | Renal Cell...
Merck Sharp & Dohme LLC

Completed

Safety, Efficacy, and Pharmacokinetics (PK) of Daptomycin (MK-3009) in Japanese Pediatric Subjects With Complicated Skin and Soft Tissue Infections (cSSTI) and Bacteremia (MK-3009-029)

Skin Diseases, Infectious | Bacteremia | Soft Tissue Infections

Japan
Eisai Inc.
Merck Sharp & Dohme LLC

Completed

Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC) (ENHANCE-1)

Breast Neoplasm

United States
Royal Marsden NHS Foundation Trust
Merck Sharp & Dohme LLC; Institute of Cancer Research, United Kingdom

Terminated

PEmbrolizumab Combined With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck (PEACH)

Squamous Cell Carcinoma of the Head and Neck | Squamous Cell Carcinoma

United Kingdom
Linda R Duska
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer

Cervical Cancer

United States
Medivir
Merck Sharp & Dohme LLC

Terminated

Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors

Solid Tumors

United States
Merck Sharp & Dohme LLC

Completed

MK-8189 Multiple Dose Study in Healthy Volunteers and Schizophrenia Participants (MK-8189-003)

Schizophrenia
Merck Sharp & Dohme LLC

Completed

Omarigliptin Add-on to Insulin in Japanese Participants With Type 2 Diabetes Mellitus (T2DM, MK-3102-039)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1)

Solid Tumors
Organon and Co

Completed

Efficacy and Safety Study of Ezetimibe (SCH 58235, MK-0653) in Addition to Atorvastatin in Participants With Coronary Heart Disease or Multiple Cardiovascular Risk Factors (P00693/MK-0653-030)

Hypercholesterolemia
Merck Sharp & Dohme LLC

Completed

Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001)

Neoplasms

3

Subscribe